

Trevigen Announces a Highly Sensitive, Fluorescent, One Hour PARP Inhibition Assay

Date: 06-23-2008 12:24 PM CET

Category: [Science & Education](#)

Press release from: [Trevigen, Inc.](#)



Poly(ADP-ribose) polymerase, through ribosylation of nuclear proteins, converts DNA Damage into intracellular signals that actuate either DNA repair or cell death. The development of inhibitors to PARP is of ever increasing interest in the drug discovery community since they can be used as modulators of DNA repair mediated resistance to cytotoxic cancer therapeutics. Until now, commercially available PARP assay kits required multiple steps and were time consuming.

Trevigen overcomes these drawbacks with the release of the HT Fluorescent Homogeneous PARP Inhibition Assay. The fluorescent assay is based on the consumption of NAD⁺ in the PARP ribosylation reaction where NAD⁺ not consumed by PARP is subsequently measured by a cycling reaction in which a highly fluorescent molecule is produced; therefore an increase in signal positively correlates to increased PARP inhibition. The subject of a Trevigen patent application, it is a simple assay requiring only 1.5 hours from start to finish. The 96 test assay requires no wash steps, and detects as little as 10% inhibition of PARP Activity. The assay is ideal for the determination of IC₅₀ values for PARP Inhibitors.

Related Products from Trevigen include PARP and PARG assay kits, PARP enzymes and PARP antibodies. Visit www.trevigen.com or contact us at 1800-873-8443 or info@trevigen.com for more information.

Trevigen, Inc.
8405 Helgerman Court
Gaithersburg, MD 20877
www.trevigen.com
info@trevigen.com
1.800.873.8443

Trevigen, Inc. is a rapidly growing biotechnology company focused on the development of products and technology for cancer research, emphasizing apoptosis, DNA damage and repair, and cancer cell function and behavior. Trevigen has been a long-standing provider of quality reagents and kits for researchers investigating programmed cell death and DNA damage and repair. A logical extension of the focus on cancer research has been the recent development of assays for cancer cell function and behavior including angiogenesis, cell invasion and tumor formation. Currently, the product portfolio contains over 500 products categorized into four processes – Apoptosis, DNA Damage and Repair, Angiogenesis, and Oxidative Stress.

[You can find this press release here](#)